Pathogenesis and Immune Response of Crimean-Congo Hemorrhagic Fever Virus in a STAT-1 Knockout Mouse Model

ABSTRACT Tick-borne Crimean-Congo hemorrhagic fever virus (CCHFV) causes a severe hemorrhagic syndrome in humans but not in its vertebrate animal hosts. The pathogenesis of the disease is largely not understood due to the lack of an animal model. Laboratory animals typically show no overt signs of disease. Here, we describe a new small-animal model to study CCHFV pathogenesis that manifests clinical disease, similar to that seen in humans, without adaptation of the virus to the host. Our studies revealed that mice deficient in the STAT-1 signaling molecule were highly susceptible to infection, succumbing within 3 to 5 days. After CCHFV challenge, mice exhibited fever, leukopenia, thrombocytopenia, and highly elevated liver enzymes. Rapid viremic dissemination and extensive replication in visceral organs, mainly in liver and spleen, were associated with prominent histopathologic changes in these organs. Dramatically elevated proinflammatory cytokine levels were detected in the blood of the animals, suggestive of a cytokine storm. Immunologic analysis revealed delayed immune cell activation and intensive lymphocyte depletion. Furthermore, this study also demonstrated that ribavirin, a suggested treatment in human cases, protects mice from lethal CCHFV challenge. In conclusion, our data demonstrate that the interferon response is crucial in controlling CCHFV replication in this model, and this is the first study that offers an in-depth in vivo analysis of CCHFV pathophysiology. This new mouse model exhibits key features of fatal human CCHF, proves useful for the testing of therapeutic strategies, and can be used to study virus attenuation.

[1]  R. Sadeghi,et al.  Nosocomial outbreak of Crimean-Congo haemorrhagic fever , 2010, Epidemiology and Infection.

[2]  J. Klingström,et al.  Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. , 2010, The Journal of general virology.

[3]  R. Rodrigues,et al.  Differential activation profiles of Crimean-Congo hemorrhagic fever virus- and Dugbe virus-infected antigen-presenting cells. , 2010, The Journal of general virology.

[4]  Ö. Ergönül Biases and misinterpretation in the assessment of the efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever , 2009 .

[5]  A. Erbay,et al.  Analysis of lymphocyte subgroups in Crimean-Congo hemorrhagic fever. , 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[6]  F. Weber,et al.  Crimean‐Congo hemorrhagic fever virus delays activation of the innate immune response , 2008, Journal of medical virology.

[7]  N. Sucu,et al.  Peripheral blood natural killer cells in Crimean-Congo hemorrhagic fever. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[8]  O. Ergonul Treatment of Crimean-Congo hemorrhagic fever. , 2008, Antiviral research.

[9]  Michael R Holbrook,et al.  Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses. , 2008, Antiviral research.

[10]  A. Kubar,et al.  Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Günther,et al.  Virus Detection and Monitoring of Viral Load in Crimean-Congo Hemorrhagic Fever Virus Patients , 2007, Emerging infectious diseases.

[12]  C. Whitehouse,et al.  Crimean-Congo Hemorrhagic Fever Virus Infection among Animals , 2007 .

[13]  Christopher B Wilson,et al.  Regulation of interferon-gamma during innate and adaptive immune responses. , 2007, Advances in immunology.

[14]  T. Purnak,et al.  Global warming may increase the incidence and geographic range of Crimean-Congo Hemorrhagic Fever. , 2007, Medical hypotheses.

[15]  O. Ergonul,et al.  Crimean-Congo hemorrhagic fever: a global perspective. , 2007 .

[16]  T. Ksiazek,et al.  Crimean-Congo Hemorrhagic Fever Virus Genomics and Global Diversity , 2006, Journal of Virology.

[17]  E. Velo,et al.  Cytokine levels in Crimean-Congo hemorrhagic fever. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[18]  O. Ergonul,et al.  Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. , 2006, The Journal of infectious diseases.

[19]  Ö. Ergönül Crimean-Congo haemorrhagic fever , 2006, The Lancet Infectious Diseases.

[20]  Å. Lundkvist,et al.  Type I interferon inhibits Crimean‐Congo hemorrhagic fever virus in human target cells , 2006, Journal of medical virology.

[21]  C. Cameron,et al.  Mechanisms of action of ribavirin against distinct viruses , 2005, Reviews in medical virology.

[22]  S. E. Smirnova A comparative study of the Crimean hemorrhagic fever-Congo group of viruses , 2005, Archives of Virology.

[23]  Chris A Whitehouse,et al.  Crimean-Congo hemorrhagic fever. , 2004, Antiviral research.

[24]  P. Jahrling,et al.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys , 2003, The Lancet.

[25]  Z. Hong,et al.  Mechanisms of Action of Ribavirin in Antiviral Therapies , 2001, Antiviral chemistry & chemotherapy.

[26]  D. Fisman Hemophagocytic syndromes and infection. , 2000, Emerging infectious diseases.

[27]  Shizuo Akira,et al.  Functional Roles of STAT Family Proteins: Lessons from Knockout Mice , 1999, Stem cells.

[28]  Lisa R Leon,et al.  Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[29]  T. Ksiazek,et al.  Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. , 1997, Archives of pathology & laboratory medicine.

[30]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[31]  R. Schreiber,et al.  Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway , 1996, Cell.

[32]  J. McCormick,et al.  Crimean Congo-Haemorrhagic Fever treated with oral ribavirin , 1995, The Lancet.

[33]  G. H. Tignor,et al.  Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection , 1993, Antiviral Research.

[34]  D. Nash,et al.  Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. , 1989, The American journal of tropical medicine and hygiene.

[35]  A. Shepherd,et al.  Viremia and antibody response of small African and laboratory animals to Crimean-Congo hemorrhagic fever virus infection. , 1989, The American journal of tropical medicine and hygiene.

[36]  A. Shepherd,et al.  The clinical pathology of Crimean-Congo hemorrhagic fever. , 1989, Reviews of infectious diseases.

[37]  C. Peters,et al.  Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. , 1989, Reviews of infectious diseases.

[38]  J. Joubert,et al.  A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part III. Clinical pathology and pathogenesis. , 1985, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[39]  A. Shepherd,et al.  A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part V. Virological and serological observations. , 1985, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[40]  O. Tomori,et al.  Experimantal Congo virus (Ib -AN 7620) infection in primates. , 1975, Virologie.

[41]  D. Simpson,et al.  Congo virus: a hitherto undescribed virus occurring in Africa. II. Identification studies. , 1967, East African medical journal.